Lymphangiomatosis is a rare proliferative disorder of the lymphatic system. The etiology is unknown, rendering it difficult to manage. This case report of lymphangiomatosis with features of Gorham's disease reveals the progressive and unexpected nature of the condition. It highlights the need for further research into the pathophysiology and management of lymphangiomatosis as current treatment options are limited.
Get full access to this article
View all access options for this article.
References
1.
VenkatramaniR, MaNS, PitukcheewanontP, MalogolowkinMH, MascarenhasL. Gorham's disease and diffuse lymphangiomatosis in children and adolescents. Pediatr Blood Cancer, 2011; 56:667–670.
2.
LeeBB, KimYW, SeoJM, HwangJH, DoYS, KimDI, ByunHS, LeeSK, HuhSH, HyunWS. Current concepts in lymphatic malformation. Vasc Endovasc Surg, 2005; 39:67–81.
3.
DaroczyJ, WolfeJ, MentzelT. Pathology. Diseases of the Lymphatics. BrowseN, BurnandK, MortimerP.Arnold Press, 2003.
4.
ShahAR, DinwiddieR, WoolfD, RamaniP, HigginsJNP, MattewDJ. Generalized lymphangiomatosis and chylothorax in pediatric age group. Pediatr Pulmonol, 1992; 14:126–130.
5.
RamaniP, ShahA. Lymphangiomatosis. Histologic and immunohistochemical analysis of four cases. Am J Surg Pathol, 1993; 17:329–335.
6.
PatelDV. Gorham's disease or massive osteolysis. Clin Med Res, 2005; 3:65–74.
7.
Bruch-GerharzD, GerharzCD, StegeH, KrutmannJ, PohlM, KoesterR, RuzickaT. Cutaneous lymphatic malformations in disappearing bone (Gorham-Stout) disease: A novel clue to the pathogenesis of a rare syndrome. J Am Acad Dermatol, 2007; 56:S21–S25.
GorhamLW, StoutAP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); Its relation to hemangiomatosis. J Bone Joint Surg Am, 1955; 37-A:985–1004.
10.
DevlinRD, BoneHG, RoodmanGD. Interleukin-6: A potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab, 1996; 81:1893–1897.
11.
DupondJ, BermontL, RungeM, de BillyM. Plasma VEGF determination in disseminated lymphangiomatosis-Gorham-Stout syndrome: A marker of activity? A case report with a 5-year follow-up. Bone, 2010; 46:873–876.
CueniLN, DetmarM. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol, 2006; 126:2167–2177.
16.
RadhakrishnanK, RocksonSG. Gorham's disease: An osseus disease of lymphangiogenesis?Ann NY Acad Sci, 2008; 1131:203–205.
17.
HammerF, KennW, WesselmannU, HofbauerLC, DellingG, AllolioB, ArltW. Gorham-Stout disease–Stabilization during bisphosphonate treatment. J Bone Miner Res, 2005; 20:350–353.
18.
HuberS, BrunsCJ, SchmidG, HermannPC, ConradC, NiessH, HussR, GraebC, JauchKW, HeeschenC, GubaM. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int, 2007; 71:771–777.
19.
AdamsDHA. Rapamycin for the treatment of complicated vascular anomalies. Pediatr Blood Cancer, 2010; 54:117.
